Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting

Rhea-AI Summary

Turning Point Therapeutics (NASDAQ: TPTX) announced four abstracts showcasing its drug candidates at the AACR annual meeting from April 10-14, 2021. Key highlights include repotrectinib's preclinical combination data with MEK inhibitors and its potency against TRK fusion proteins. The company will also present data on TPX-0022's utility with immune checkpoint inhibitors and TPX-0131’s efficacy against ALK resistance mutations. These presentations could provide insights into the drugs' potential market impact and clinical applications.

Positive

• Presentation of four abstracts at AACR potentially enhances awareness of drug candidates.
• Repotrectinib shows promising preclinical data combining with MEK inhibitors, indicating increased effectiveness.
• TPX-0022 demonstrates potential utility alongside immune checkpoint inhibitors.
• TPX-0131 displays activity against ALK resistance mutations, important for treating resistant cancers.

Negative

• None.

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced today that four abstracts featuring three of its drug candidates will be presented at the American Association for Cancer Research (AACR) annual meeting, which will convene virtually from April 10-14.

For lead drug candidate, repotrectinib, two poster presentations will highlight new preclinical combination data with MEK and MEK/Raf inhibitors, as well as repotrectinib’s potency against wildtype and TRKC A/B/C as compared to approved TRK inhibitors. For MET/SRC/CSF1R inhibitor, TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors. For its newest drug candidate, ALK-inhibitor TPX-0131, Turning Point will present preclinical potency data against ALK resistance mutations and in-vivo data demonstrating brain tissue penetration.

The four posters to be presented are:

Title: Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models
Abstract Number: 1104

Title: Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity
Abstract Number: 1119

Title: TPX-0022, a potent MET/SRC/CSF1R inhibitor that modulates the tumor immune microenvironment in preclinical models
Abstract Number: 1444

Title: TPX-0131, a potent inhibitor of wild type ALK and a broad spectrum of both single and compound ALK resistance mutations
Abstract Number: 1469

AACR plans to make poster presentations available via its website on Sat., April 10, the first day of the virtual Annual Meeting.

About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics’ drug candidates, the results, conduct, progress and timing of Turning Point Therapeutics’ pre-clinical studies and plans regarding future development activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272

 

FAQ

What are the key highlights from Turning Point Therapeutics' press release regarding TPTX?

Turning Point is presenting four abstracts at the AACR annual meeting, focusing on drug candidates like repotrectinib, TPX-0022, and TPX-0131, showcasing their efficacy and potential combinations.

When is the AACR annual meeting where Turning Point will present its abstracts?

The AACR annual meeting will take place virtually from April 10 to April 14, 2021.

What is the significance of repotrectinib's data presented by Turning Point?

Repotrectinib's data highlights its increased effectiveness in combination with MEK inhibitors and its potency against TRK fusion proteins, which may enhance its therapeutic potential in cancer treatment.

How is TPX-0022 expected to work in combination with other therapies?

TPX-0022 is showing preclinical data suggesting its efficacy in combination with immune checkpoint inhibitors, which could improve treatment outcomes for patients with advanced cancers.

What does the data on TPX-0131 from Turning Point suggest?

The data on TPX-0131 indicates its potency against ALK resistance mutations, highlighting its potential as a treatment option for patients with ALK-positive cancers.